Drug or intervention
Tirzepatide Clinical Trials
Studies that test Tirzepatide, alone, with other treatments or as the comparison.
In numbers
Open to volunteers: recruiting, not yet recruiting or enrolling by invitation. Active adds studies under way that have stopped recruiting.
Open to volunteers
All 171Overweight and Obesity
A Phase 1/2a Study of WVE-007 in Adults Living With Overweight or Obesity
The purpose of this study is to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of ascending doses of WVE-007 when administered subcutaneously (SC) .
- Trial name
- INLIGHT (NCT06842186)
- Testing
- WVE-007
- Where
- 7 sites in United States, Moldova and 2 more
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Wave Life Sciences USA, Inc.
Obese Adults
Effects of Tirzepatide on Esophagogastric Junction Mechanics, Reflux Burden, and Gastric Physiology in Adults With Obesity
This study will assess whether a single subcutaneous dose of tirzepatide 7.5 mg , compared with saline placebo, increases total esophageal acid exposure time during a 96-hour wireless pH recording beginning about 48 hours after…
- Trial name
- NCT07893457
- Testing
- Tirzepatide
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Mayo Clinic
Methamphetamine Use Disorder
Randomized Controlled Trial of Tirzepatide for Methamphetamine Use Disorder
This is a phase 2, randomized, double-blind, placebo-controlled, parallel-group trial evaluating the tolerability, safety, and preliminary efficacy of tirzepatide for the treatment of individuals with moderate or severe…
- Trial name
- T-STEM (NCT07825857)
- Testing
- Tirzepatide
- Where
- 4 sites in United States
- Volunteers
- 228 people
- Sponsor
- University of Texas Southwestern Medical Center
Type 2 Diabetes Mellitus
A Clinical Study to Evaluate the Effects of Enicepatide Versus Tirzepatide in Participants With Type 2 Diabetes and Inadequate Blood Sugar Control on Oral Glucose-Lowering Medications
The study will evaluate the efficacy and safety of enicepatide, a glucagon-like peptide-1/glucose-dependent insulinotropic polypeptide receptor (GLP-1/GIP) receptor agonist (RA), compared with tirzepatide among participants with…
- Trial name
- ENI-SPIRE-2 (NCT07889648)
- Testing
- Enicepatide, Tirzepatide
- Volunteers
- 948 people
- Sponsor
- Hoffmann-La Roche
Liver Cirrhoses, Portal Hypertension Related to Cirrhosis
Optimizing Portal Hypertension With TIPS and Interval Metabolic Surgery for Advanced Liver Disease
Cirrhosis is a form of advanced liver disease that can lead to serious complications, especially when combined with severe obesity.
- Conditions
- Liver Cirrhoses, Portal Hypertension Related to Cirrhosis, Severe Obesity, TIPS
- Trial name
- OPTIMAL (NCT07058155)
- Testing
- Transjugular Intrahepatic Portosystemic Shunt (TIPS), Sleeve Gastrectomy, Anti-Obesity Pharmacotherapy (Class Effect)
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- The Cleveland Clinic
Endometrioid Endometrial Adenocarcinoma
A Study to Estimate Early Clinical Efficacy Signals of GLP-1 Agonist Administration in Conjunction With Levonorgestrel Intrauterine Device in Obese Patients With Endometrioid Intraepithelial Neoplasia
This study will explore the use of glucagon-like peptide 1 receptor agonist (GLP-1RA) used concurrently with levonorgestrel intrauterine device in patients with poor surgical candidacy for a hysterectomy or patients who are…
- Trial name
- NCT07107334
- Testing
- Glucagon-like peptide 1 receptor agonist
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of Florida
Sarcoma,Soft Tissue
PROACT AYA: Preventing Overweight/Obesity-Associated Cardiotoxicity With Tirzepatide In Adolescent And Young Adult Cancer Survivors - A Phase 2 Single-Arm, Single-Center Feasibility Study
This is a prospective, single-arm, open-label feasibility trial conducted at the MD Anderson Sarcoma Center and Cardio-Oncology Clinic.
- Trial name
- NCT07874828
- Testing
- Tirzepatide
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- M.D. Anderson Cancer Center
Obesity (BMI>30)
Resistance Training to Prevent Muscle Loss During Treatment With Tirzepatide
Incretin-based pharmacotherapies induce significant weight loss and represent a paradigm shift in obesity treatment. However, particularly fast weight loss may be accompanied by a significant loss of muscle mass, which is…
- Trial name
- RESIST (NCT07777575)
- Testing
- Dual GIP/GLP-1 Receptor Agonist Tirzepatide, Resistance Training
- Where
- Germany
- Volunteers
- 150 people
- Sponsor
- Technical University of Munich
Obesity
Tirzepatide Titration to Reduce Side Effects in Individuals With Obesity
The goal of this clinical trial is to determine whether a flexible, symptom-guided titration strategy for tirzepatide can help adults with obesity without diabetes stay on treatment longer, while maintaining weight-loss…
- Trial name
- TiTRE (NCT07574723)
- Testing
- Tirzepatide (Per-label titration), Tirzepatide (Flexible titration)
- Where
- Kuwait
- Volunteers
- 68 people
- Sponsor
- Dasman Diabetes Institute
Plaque Psoriasis
A Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy
The main aim of this study is to assess whether secukinumab treatment retention over 12 months in adult patients with moderate-to-severe plaque PsO receiving secukinumab in combination with a GLP-1 RA is non-inferior to that in…
- Trial name
- STAY SEC PsO (NCT07881783)
- Volunteers
- 3,718 people
- Sponsor
- Novartis Pharmaceuticals
Completed, with results posted
All 47Type 2 Diabetes Mellitus
A Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes
The purpose of the trial is to assess the efficacy and safety of tirzepatide to dulaglutide in participants with type 2 diabetes and increased cardiovascular risk.
- Trial name
- SURPASS-CVOT (NCT04255433)
- Testing
- Tirzepatide, Dulaglutide
- Where
- 635 sites in United States, Argentina and 29 more
- Volunteers
- 13,299 people
- Sponsor
- Eli Lilly and Company
Triglycerides, Weight Gain Trajectory
Effects of RDX-002 on Postprandial Triglycerides in Patients Discontinuing GLP-1 Agonists
The goal of this clinical trial is to learn if drug RDX-002 works to treat high levels of fat (known as triglycerides, or TGs) in the blood in adults. It will also learn about the safety of drug RDX-002.
- Conditions
- Triglycerides, Weight Gain Trajectory, Cholesterol, Elevated
- Trial name
- NCT06640972
- Testing
- RDX-002
- Where
- United States
- Volunteers
- 68 people
- Sponsor
- Response Pharmaceuticals
Diabetes Mellitus, Type 2, Obesity
Holding vs. Continuing Incretin-based Therapies Before Upper Endoscopy
To assess whether holding incretin-based therapy before endoscopy reduces the likelihood of clinically relevant Residual Gastric Volume (RGV).
- Conditions
- Diabetes Mellitus, Type 2, Obesity, Gastroparesis
- Trial name
- NCT06533527
- Testing
- GLP-1 medication
- Where
- 2 sites in United States
- Volunteers
- 69 people, healthy volunteers welcome
- Sponsor
- The Cleveland Clinic
Obesity, Overweight
A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight With Weight Related Comorbidities
The main purpose of this phase 3b study is to evaluate the efficacy and safety of tirzepatide compared with semaglutide in adult participants who have obesity or overweight with weight related comorbidities without Type 2…
- Trial name
- SURMOUNT-5 (NCT05822830)
- Testing
- Tirzepatide, Semaglutide
- Where
- 32 sites in United States, Puerto Rico
- Volunteers
- 751 people
- Sponsor
- Eli Lilly and Company
Type 2 Diabetes
A Study of Tirzepatide (LY3298176) in Chinese Participants With Type 2 Diabetes (SURPASS-CN-MONO)
The main purpose of this study is to investigate the efficacy and safety of Tirzepatide monotherapy in Chinese participants with Type 2 Diabetes.
- Trial name
- NCT05963022
- Testing
- Tirzepatide
- Where
- 28 sites in China
- Volunteers
- 206 people
- Sponsor
- Eli Lilly and Company